1131 - Evaluation of drug-drug interaction potential of ensitrelvir for CYP3A by clinical studies and physiologically-based pharmacokinetic model

Friday, October 21, 2022

12:15 PM – 1:30 PM US ET

Location: Hall B + C

Presenting Author(s)

Ryosuke Shimizu

Manager
Clinical Pharmacology & Pharmacokinetics, Project Management Department, Shionogi & Co., Ltd. Osaka, Japan
Osaka, Osaka, Japan

Kana Horiuchi

Scientist
Laboratory for Drug Discovery and Development, Shionogi & Co., Ltd., Osaka, Japan
Toyonaka, Osaka, Japan
HK

Hiroki Koshimichi, n/a

Scientist
Clinical Pharmacology & Pharmacokinetics, Project Management Department, Shionogi & Co., Ltd. Osaka, Japan
Osaka, Osaka, Japan
TM

Takanobu Matsuzaki, Ph.D.

Laboratory for Drug Discovery and Development, Shionogi & Co., Ltd., Osaka, Japan
Toyonaka, Osaka, Japan
SY

Shinpei Yoshida, Ph.D.

Laboratory for Drug Discovery and Development, Shionogi & Co., Ltd., Osaka, Japan
Toyonaka, Osaka, Japan
SS

Shingo Sakamoto, n/a

Laboratory for Drug Discovery and Development, Shionogi & Co., Ltd., Osaka, Japan
Toyonaka, Osaka, Japan
RK

Ryuji Kubota, Ph.D.

Clinical Pharmacology & Pharmacokinetics, Project Management Department, Shionogi & Co., Ltd. Osaka, Japan
Osaka, Osaka, Japan